Taking production of your sterile drug product from clinical to commercial scale is a complicated and challenging process with many factors to consider. This is particularly true when it comes to the scale-up of aseptic manufacturing processes, which are increasingly common in the pharmaceutical industry.

In this blog post, Rob Lee, President, and Jason Steele, Director of Business Development at the CDMO Division of LLS Health, explore key considerations when selecting a sterile manufacturing partner.

Click here to read the full blog How to Select the Right CDMO for Your Sterile Drug Product from Lubrizol Life Science.

Finding the right manufacturing partner to bring your product from clinical to commercial production demands a careful balance of technical expertise and cultural fit. For example, many contract manufacturing organizations (CMOs) concentrate on high-volume products and may not offer the flexibility and partnership needed to scale up a new drug product. Other contract partners may offer great flexibility and collaborative personnel, but not have the right aseptic processing expertise or facilities for your product. Selecting a manufacturing organization requires a thorough evaluation of both science and talent.

Click here to learn more about our available aseptic manufacturing capacity and schedule a call with an expert from Lubrizol Life Science.